Tides Medical is announcing the launch of two novel amniotic membrane products, Artacent Flex and Artacent Wound. The two tissue products are the first to be processed in Tides Medical’s new, state-of-the art tissue processing facility located in Lafayette, La. According to CEO Joe Spell, “We have been a successful private labeler of amniotic tissues for several years. This launch and the opening of our own tissue bank show our commitment to being a leader in the rapidly expanding market for donated amniotic tissue grafts.”
Artacent Flex is the original dual-layer amniotic graft designed specifically as a surgical barrier. Artacent Wound is a wound-specific, dual-layer amniotic graft designed for ease-of-use. Both products will be on display this week at the Tides Medical booth, number 1015, at the American College of Foot and Ankle Surgeons annual meeting in Austin, Texas.
Concurrent with the launch, Tides Medical is beginning a large, multi-center, randomly controlled trial comparing Artacent Wound to standard-of-care treatment for diabetic and venous stasis ulcers. According to Vice President of Research Isabella Sledge, M.D., MPH, “This study is designed to be the most powerful study comparing amniotic membrane tissue therapies to current standard of care for the treatment of chronic wounds.”